Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedFeb 26, 2026
DataAggregated Company Financials
Companies62
  • 7D-0.5%
  • 3M-15.2%
  • 1Y-5.3%
  • YTD-13.4%

The Life Sciences industry has been flat over the last week, but IQVIA Holdings has lost 5.3%. As for the longer term, the industry has declined 5.3% in the last year. Looking forward, earnings are forecast to grow by 16% annually.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 26 Feb 2026US$593.7bUS$147.8bUS$14.0b34.7x42.5x4x
Sat, 24 Jan 2026US$709.3bUS$145.8bUS$12.4b36x57.4x4.9x
Mon, 22 Dec 2025US$651.7bUS$145.8bUS$12.5b34.7x52.2x4.5x
Wed, 19 Nov 2025US$640.9bUS$145.7bUS$12.2b34x52.6x4.4x
Fri, 17 Oct 2025US$617.9bUS$144.3bUS$14.6b32.8x42.5x4.3x
Sun, 14 Sep 2025US$565.3bUS$144.3bUS$14.6b28.6x38.8x3.9x
Tue, 12 Aug 2025US$550.8bUS$144.2bUS$14.4b29x38.2x3.8x
Thu, 10 Jul 2025US$543.5bUS$142.9bUS$9.1b36.5x59.5x3.8x
Sat, 07 Jun 2025US$509.9bUS$142.9bUS$9.2b35.6x55.6x3.6x
Mon, 05 May 2025US$523.7bUS$142.4bUS$9.7b37.8x54.3x3.7x
Wed, 02 Apr 2025US$572.5bUS$142.5bUS$10.0b36.7x57.4x4x
Fri, 28 Feb 2025US$616.3bUS$143.3bUS$9.7b37.7x63.3x4.3x
Sun, 26 Jan 2025US$700.4bUS$142.4bUS$10.2b45.1x68.6x4.9x
Tue, 24 Dec 2024US$652.4bUS$142.4bUS$10.2b43.7x63.8x4.6x
Thu, 21 Nov 2024US$634.5bUS$142.4bUS$10.4b42x61.3x4.5x
Sat, 19 Oct 2024US$729.7bUS$141.8bUS$8.5b37.2x85.9x5.1x
Mon, 16 Sep 2024US$740.7bUS$141.8bUS$8.5b37.5x87.2x5.2x
Wed, 14 Aug 2024US$724.4bUS$141.5bUS$8.4b39x86.7x5.1x
Fri, 12 Jul 2024US$669.1bUS$141.3bUS$12.2b40.5x54.9x4.7x
Sun, 09 Jun 2024US$713.3bUS$141.3bUS$12.2b37.7x58.6x5x
Tue, 07 May 2024US$714.1bUS$141.7bUS$12.5b39.7x57.1x5x
Thu, 04 Apr 2024US$727.8bUS$142.1bUS$12.8b43.1x56.9x5.1x
Sat, 02 Mar 2024US$735.4bUS$142.2bUS$12.8b44.2x57.4x5.2x
Mon, 29 Jan 2024US$698.4bUS$153.8bUS$14.2b35.5x49.3x4.5x
Wed, 27 Dec 2023US$698.9bUS$153.8bUS$14.2b37.8x49.1x4.5x
Fri, 24 Nov 2023US$631.0bUS$153.8bUS$14.0b33.5x45x4.1x
Sun, 22 Oct 2023US$607.7bUS$154.6bUS$11.2b31.3x54.2x3.9x
Tue, 19 Sep 2023US$688.5bUS$154.6bUS$11.2b32.7x61.4x4.5x
Thu, 17 Aug 2023US$708.0bUS$154.6bUS$11.2b32.3x63.2x4.6x
Sat, 15 Jul 2023US$706.2bUS$155.5bUS$12.7b29.3x55.7x4.5x
Mon, 12 Jun 2023US$680.2bUS$152.4bUS$12.5b29.1x54.4x4.5x
Wed, 10 May 2023US$685.2bUS$152.2bUS$12.8b30.1x53.6x4.5x
Fri, 07 Apr 2023US$719.9bUS$154.6bUS$10.8b26.7x66.6x4.7x
Sun, 05 Mar 2023US$739.7bUS$154.5bUS$10.9b31x68x4.8x
Price to Earnings Ratio

68x


Total Market Cap: US$739.7bTotal Earnings: US$10.9bTotal Revenue: US$154.5bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 58.5x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 42.5x which is lower than its 3-year average PE of 58.5x.
  • The 3-year average PS ratio of 4.5x is higher than the industry's current PS ratio of 4.0x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 8.7% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.90%
Healthcare0.17%
Life Sciences-0.54%
Clinical Research and Equipment-0.54%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
DHR DanaherUS$209.520.5%
+US$728.8m		0.04%PE41.2x
CRL Charles River Laboratories InternationalUS$167.566.1%
+US$472.6m		-0.2%PS2.1x
ICLR ICONUS$101.004.7%
+US$343.6m		-48.5%PE12.9x
ILMN IlluminaUS$121.871.5%
+US$272.2m		29.6%PE21.9x
MTD Mettler-Toledo InternationalUS$1.38k0.3%
+US$88.2m		7.0%PE32.3x

Latest News

TMO
US$513.68
Thermo Fisher Scientific
7D
0.02%
1Y
-3.7%
TEM
US$53.71
Tempus AI
7D
-4.4%
1Y
-13.7%
MRVI
US$3.26
Maravai LifeSciences Holdings
7D
9.4%
1Y
0.3%
CRL
US$167.56
Charles River Laboratories International
7D
6.1%
1Y
-0.2%
A
US$124.72
Agilent Technologies
7D
-1.7%
1Y
-7.3%

A: New Diagnostic Approvals Will Support Measured Upside Ahead

Analysts reaffirm a price target of $169.67 for Agilent Technologies, citing largely unchanged assumptions for the discount rate, revenue growth, profit margin, and future P/E. These factors together keep their valuation framework intact.
DHR
US$209.52
Danaher
7D
0.5%
1Y
0.04%
MTD
US$1,379.91
Mettler-Toledo International
7D
0.3%
1Y
7.0%

MTD: Buybacks And 2026 Sales Outlook Will Support Balanced Return Prospects

Analysts have maintained their $1,501 fair value estimate for Mettler-Toledo International while slightly adjusting underlying assumptions such as the discount rate, revenue growth, profit margin and future P/E. These changes reflect updated views on the company’s risk profile and earnings power without altering the overall price target.
ILMN
US$121.87
Illumina
7D
1.5%
1Y
29.6%
SHC
US$16.16
Sotera Health
7D
-7.1%
1Y
31.6%

SHC: Organic Investment And Deleveraging Will Support Future Upside Potential

Analysts have kept their Sotera Health price target effectively unchanged at about $20.44, reflecting minimal updates to assumptions around the discount rate, long term revenue growth, profit margins, and future P/E expectations. What's in the News Sotera Health signaled that its primary use of capital remains focused on organic growth, with management highlighting continued investment to strengthen existing businesses.
RGEN
US$132.14
Repligen
7D
-4.3%
1Y
-18.8%

RGEN: M&A Focus And New Bioprocessing Resins Will Drive Future Upside

Analysts have raised their Repligen price target by $10 to $190.89, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E as reflected in recent Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the higher US$190.89 price target as better aligned with updated assumptions for discount rates and future P/E, suggesting the shares may not fully reflect their revised valuation framework.
ICLR
US$101.00
ICON
7D
4.7%
1Y
-48.5%

ICLR: Oncology Expansion And Accounting Overhang Are Expected To Reset Sentiment

Analysts have lowered their average price target on ICON from about $206 to roughly $155 as they factor in the ongoing internal accounting investigation, modestly softer growth and margin assumptions, a slightly higher discount rate, and a reduced future P/E multiple, even as some describe the recent share price weakness as creating a more compelling entry point. Analyst Commentary Recent research on ICON reflects a split view, with some analysts turning more constructive after the share price pullback while others remain cautious given the internal accounting investigation and softer growth and margin assumptions.
WAT
US$319.44
Waters
7D
-2.5%
1Y
-17.0%

WAT: Reorganization And Margin Pressure Will Likely Cap Upside For Now

Analysts now mark their price target for Waters at $330, down from $349, citing updated assumptions around revenue growth, profit margins, discount rate, and future P/E that change their overall valuation framework. What's in the News Waters closed a transaction and reorganized into four divisions focused on high-volume testing and adjacent markets, now grouped as Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences (company announcement).
STVN
US$15.30
Stevanato Group
7D
-5.7%
1Y
-26.7%
MEDP
US$438.08
Medpace Holdings
7D
-1.8%
1Y
29.0%
ADPT
US$16.21
Adaptive Biotechnologies
7D
2.1%
1Y
93.9%

ADPT: Pfizer Agreements And MRD Progress Will Support Future Upside Potential

Analysts have nudged their average price target for Adaptive Biotechnologies higher by about $1, reflecting updated fair value assumptions and slightly revised views on growth, margins and future P/E, in line with recent target increases from several research firms. Analyst Commentary Recent research updates cluster around modest target increases and a generally supportive view of Adaptive Biotechnologies, with most of the focus on refreshed fair value work rather than sweeping changes to the thesis.
IQV
US$161.91
IQVIA Holdings
7D
-5.3%
1Y
-15.2%

IQV: Stronger 2026 Demand Visibility Supports Backlog And Margin Improvement Potential

Analysts have trimmed their average 12 month price target for IQVIA by around $70 to reflect updated Q4 guidance, ongoing work to factor in potential long term AI risks for contract research organizations, and recalibrated expectations for growth, margins, and future P/E multiples. Analyst Commentary Recent Street research shows a split view on IQVIA, with some firms trimming targets after Q4 guidance while others highlight areas where execution and demand trends still support a more constructive stance on the stock.